Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
EXEL · against 121 other Healthcare companies of similar size
Ranked #41 of 122 · scores higher than 66% of peers
Bars: peers in each 10-point band of the valuation score24 peers with a valuation score of 60–69, including EXEL · Click a bar to see the companies
Mainly thanks to its free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
| Metric | EXEL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 120 reported | 4.4% | 3.1% | 76% | 30% | |
| EBITDA yieldHigher is better · 123 reported | 5.9% | 5.2% | 55% | 50% | |
| Free cash flow yieldHigher is better · 79 reported | 6.5% | 3.5% | 81% | 20% | |
| Book yieldHigher is better · 117 reported | 10.2% | 21.0% | 22% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 2 | 10.4B USD | 96 | 64 | |
| 3 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 3 | 21.5B USD | 95 | 60 | |
| 5 | 11.6B USD | 94 | 58 | |
| 35 | 154.4B BRL (≈$27.8B) | 69 | 43 | |
| 35 | 101.7B BRL (≈$18.3B) | 69 | 58 | |
| 39 | 13.9B EUR (≈$15.3B) | 68 | 78 | |
| 39 | 32.8B USD | 68 | 69 | |
| 41 | 17.9B USD | 67 | 76 | |
| 41 | 133.4B BRL (≈$24.0B) | 67 | 49 | |
| 43 | 83.0B CNY (≈$11.6B) | 66 | 62 | |
| 43 | 27.3B USD | 66 | 55 | |
| 45 | 177.2B HKD (≈$22.7B) | 65 | 73 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score